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Abstract
Primary fallopian tube carcinoma is the least common of the gynecologi-
cal malignancies and rarely diagnosed preoperatively. We report the case 
of a 70-year-old woman with primary tubal carcinoma, which was diag-
nosed preoperatively on the basis of elevated CA125 and characteristic 
features found by transvaginal sonography, transvaginal color flow imaging 
and magnetic resonance imaging. Transvaginal ultrasonography showed a 
sausage-shaped solid mass alongside the right ovary. Transvaginal color 
Doppler imaging revealed characteristically low impedance vascular flow 
within the solid components. A pathohistological study confirmed the 
diagnosis of fallopian tube carcinoma. [Tzu Chi Med J 2010;22(4):
225–228]
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1. Introduction
Primary adenocarcinoma of the fallopian tube com-
prises only 0.3% of all gynecological cancers [1]. In 
many patients, fallopian tube carcinoma is asymptom-
atic. A definite preoperative diagnosis of fallopian 
tube cancer is made in only 3–15% of patients, and 
the usual clinical diagnosis is an ovarian tumor or 
pelvic inflammatory disease [1–4]. The aim of this 
paper is to discuss the clinical presentation, trans-
vaginal sonography results and magnetic resonance 
imaging (MRI) features of fallopian tube carcinoma 
as well as the role of the tumor marker CA125 in its 
diagnosis. Furthermore, we assess the response and 
follow-up to the postsurgical treatment and chemo-
therapy of the epithelial ovarian cancer.
2. Case report
A 70-year-old, gravida 4, para 4, woman came to our 
hospital due to a dull pain over her right lower abdo-
men, but no serosanguineous vaginal discharge or 
postmenopausal bleeding. Pap smear was normal. 
Transvaginal ultrasonography showed a sausage-
shaped solid mass measuring 7 × 3 cm alongside the 
right ovary. Doppler flow indicated a flow with a resis-
tance index of 0.33 (Fig. 1). The patient’s CA125 an-
tigen level was 173 U/mL. MRI of the whole abdomen 
with and without contrast enhancement revealed a 
tubular tumor mass (7.99 × 2.89 cm) in the right pelvic 
cavity r/o salpinx tumor, unremarkable changes to 
the liver, spleen and pancreas, no enlarged lymph 
nodes in the pelvic and para-aortic regions and no 
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ascites (Fig. 2). She underwent total hysterectomy, 
bilateral salpingo-oophorectomy, infracolic omen-
tectomy, and pelvic and para-aortic lymph node sam-
pling. No macroscopic disease was left following the 
operation.
Microscopically, sections of right fallopian tube 
and ovary showed the presence of moderately differ-
entiated adenocarcinoma that was characterized by 
crowded complex branching neoplastic glands with 
a cribriform to glandular architecture or back-to-back 
glands without intervening stroma. The tumor cells 
exhibited dot-like nucleoli within hyperchromatic nu-
clei with mild to moderate pleomorphism, coarse 
chromatin and mild mitotic figures. The serosal layers 
were unremarkable (Fig. 3). There were no metastatic 
tumors in the pelvic and para-aortic lymph nodes, 
and the abdominal cytology was negative. The FIGO 
stage was assessed to be stage IIA.
Two months later, the patient was treated with six 
courses of adjuvant chemotherapy including taxol/
cisplatin chemotherapy. CA125 decreased to a normal 
level after two courses of chemotherapy. One year 
after the operation, MRI revealed no evidence of recur-
rence and CA125 levels remained normal. The patient 
continues to receive regular follow-up at our hospital.
3. Discussion
The most common presentation of fallopian tube 
cancer is vaginal bleeding and discharge (50–60%) 
followed by abdominal pain (30–49%) and abdominal 
mass (12–61%) [1–4]. Abdominal pain can be col-
icky (as a result of forced tubal peristalsis) or dull (as 
a result of tube distension). Latzko’s triad of symp-
toms, consisting of intermittent profuse serosan-
guineous vaginal discharge, colicky pain relieved by 
discharge, and an abdominal or pelvic mass, is re-
ported in only 15% of patients [2–4]. Most patients 
have a delay in diagnosis, and early clinical suspicion 
helps early diagnosis. In our case, the patient pre-
sented only with right lower abdominal dull pain but 
did not have serosanguineous vaginal discharge or 
postmenopausal bleeding. A pap smear was normal.
The sonographic appearance of fallopian tube car-
cinoma can be nonspecific and may mimic other pel-
vic diseases such as tubo-ovarian abscess, ovarian 
tumor, and ectopic pregnancy. Reported features in-
clude a sausage-shaped mass, cystic spaces with mural 
nodules and a multilobular mass with a cog and wheel 
Fig. 1 — Transvaginal ultrasonography shows a sausage-
shaped solid mass measuring 7 ´  3 cm alongside the right 
ovary (ROV). Doppler flow indicates a flow with a resistance 
index of 0.33.
Fig. 2 — Magnetic resonance imaging shows a tubular 
tumor mass (7.99 ´  2.89 cm) in the right pelvic cavity r/o 
salpinx tumor.
Fig. 3 — Adenocarcinoma of the fallopian tube (hematox-
ylin & eosin, 400´). The tumor (double arrows) contains 
pseudolumina and hyperchromatic nuclei within the neo-
plastic cells. A portion of the fallopian tube (single arrow) 
is presented in the lower portion of the figure.
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appearance in the adnexal region [5–8]. Low imped-
ance vascular flow within the solid components has 
been observed in some cases [5–8]. In our case, trans-
vaginal ultrasonography showed a sausage-shaped 
solid mass measuring 7 × 3 cm alongside the right 
ovary. Doppler flow showed low vascular impedance 
with a resistance index of 0.33. With both computed 
tomography (CT) and MRI, the lesion can appear rela-
tively solid, and lobulated when not associated with 
hydrosalpinx. Associated CT and MRI findings include 
peritumoral ascites, intrauterine fluid collection, and 
hydrosalpinx [9,10]. Importantly, MRI is superior to CT 
and ultrasound when identifying local tumor infiltration 
of the bladder, pelvic fat, vagina, pelvic sidewalls, and 
bowel [9,10].
Serum CA125 is used routinely as a tumor marker 
for diagnosis, assessing response to treatment and 
follow-up of epithelial ovarian cancer. Although 
CA125 is not diagnostic of fallopian tube cancer, 
more than 80% patients have elevated pretreatment 
serum CA125 levels and 87% of tumor tissues stain 
positively for CA125 [11,12]. Pretreatment serum 
CA125 level is an independent prognostic factor of 
disease-free status and overall survival in patients 
with fallopian tube cancer. If elevated, serum CA125 
level also adequately defines the response to chemo-
therapy [11,12]. In 90% of patients, an increase in 
serum CA125 level precedes clinical or radiological 
diagnosis of recurrent disease with a median lead 
time of 3 months (range, 0.5–7 months) [11,12]. In 
our case, the patient had an elevated pretreatment 
serum CA125 level of 173 U/mL, which decreased to 
a normal level after two courses of chemotherapy. 
One year postoperatively, her CA125 levels remain 
normal.
The diagnosis of fallopian tube carcinoma is not 
often made preoperatively and may not be made 
even on initial surgery. This means that correct stag-
ing may not be performed at the time of the initial 
operation. In advanced disease, postoperative resid-
ual disease larger than 2 cm can have an adverse 
prognostic impact [13–16]. Aggressive debulking 
should be attempted in patients with an advanced 
tumor. Surgery should consist of bilateral salpingo-
oophorectomy, total abdominal hysterectomy, and 
comprehensive surgical staging [13–16]. Patients 
with advanced disease should undergo paclitaxel-
containing regimens, including cisplatin/carboplatin 
and a standard combination of cyclophosphamide, 
adriamycin, and platinum (CAP) chemotherapies 
[17–22]. Our patient underwent total hysterectomy, 
bilateral salpingo-oophorectomy, infracolic omentec-
tomy, and pelvic lymph node and para-aortic sam-
pling. No macroscopic disease was left following the 
operation. There were no metastatic tumors present 
in the pelvic and para-aortic lymph nodes and the 
abdominal cytology was negative. The FIGO stage 
was assessed to be stage IIA. Two months later, the 
patient was treated by adjuvant chemotherapy in-
cluding cisplatin/taxol chemotherapy, and CA125 
decreased to a normal level after two courses of 
chemotherapy.
In summary, primary carcinoma of the fallopian 
tube can be strongly suspected preoperatively on 
the basis of its characteristic clinical symptoms, an 
elevated CA125 level, a transvaginal sonographic in-
vestigation, and MRI findings.
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